To examine the association of sociodemographic, healthcare, and clinical factors with metabolic bariatric surgery (MBS) uptake among individuals with employer-based insurance and an incident obesity diagnosis, addressing critical gaps in obesity treatment.
Approach:
Key Findings:
The uptake of MBS remains low at approximately 1% of the clinically eligible population each year, indicating a significant treatment gap.
Factors such as underdiagnosis of obesity, lack of physician education, stigma, and bias contribute to low MBS uptake, highlighting systemic issues in healthcare.
Disparities in MBS uptake exist across demographic factors, including race, ethnicity, sex, and socioeconomic status, necessitating targeted interventions.
Interpretation:
The study highlights the multifaceted barriers to MBS uptake, emphasizing the need for improved education and communication regarding obesity treatment options, which could inform policy changes.
Limitations:
The study was exempt from institutional review board review, which may limit generalizability and raise concerns about data integrity.
Data were derived from a single insurance claims database, potentially affecting the diversity of the cohort and introducing selection bias.
Conclusion:
Further research is urgently needed to explore the combination of GLP-1 receptor agonists and MBS in treating obesity, particularly for individuals with higher BMIs, to enhance treatment efficacy.
